ROCKWELL MEDICAL, INC. Financial Summary

Quick Answer

ROCKWELL MEDICAL, INC. reported Total Revenue of $57.30 million for fiscal year 2017.

ROCKWELL MEDICAL, INC. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue
Net Income -$5.31M
-1007.1%
-$480.0K
+94.3%
-$8.44M
+54.8%
-$18.68M
+42.8%
-$32.67M
-5.8%
-$30.89M
+9.5%
Diluted EPS -$0.15
-400.0%
-$0.03
+91.9%
-$0.37
+71.8%
-$1.31
+65.8%
-$3.83
-834.1%
-$0.41
Total Assets $57.15M
-3.5%
$59.21M
+13.5%
$52.17M
+11.9%
$46.63M
-4.0%
$48.57M
-37.5%
$77.75M
+75.4%
Cash and Equivalents $10.71M
-31.6%
$15.66M
+74.4%
$8.98M
-11.1%
$10.10M
-23.9%
$13.28M
-72.7%
$48.68M
+312.7%
Long-Term Debt $8.83M
+4.2%
$8.47M
+2.2%
$8.29M
+9.8%
$7.55M
-42.7%
$13.19M
-37.1%
$20.95M
Stockholders Equity $36.98M
+13.5%
$32.59M
+53.1%
$21.29M
+50.9%
$14.11M
+456.4%
$2.54M
-92.6%
$34.17M
+68.2%
R&D Expense $0.00
-100.0%
$19.0K
-98.3%
$1.11M
Operating Income -$4.69M
-871.5%
$608.0K
+109.1%
-$6.67M
+60.3%
-$16.78M
+44.7%
-$30.34M
-6.7%
-$28.42M
+17.7%
Gross Profit $11.70M
-33.1%
$17.48M
+100.9%
$8.70M
+113.5%
$4.08M
+268.5%
-$2.42M
-188.8%
$2.73M
-4.0%
Shares Outstanding 39.41M
+15.7%
34.06M
+16.9%
29.13M
+139.5%
12.16M
+42.4%
8.54M
-90.9%
93.57M
+43.1%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2017 $14.63M +14.1% +10.4%
Net Income September 30, 2025 -$1.75M -205.3% -17.5%
Diluted EPS September 30, 2025 -$0.05 -225.0% +0.0%
Total Assets September 30, 2025 $57.49M +0.7% +9.2%
Cash and Equivalents September 30, 2025 $13.61M +10.3% +9.0%
Long-Term Debt September 30, 2025 $8.74M +4.2% +1.0%
Stockholders Equity September 30, 2025 $37.02M +27.1% +21.7%
R&D Expense September 30, 2025 $0.00
Operating Income September 30, 2025 -$1.58M -181.8% -17.4%
Gross Profit September 30, 2025 $2.27M -63.6% -9.2%
Shares Outstanding September 30, 2025 39.41M +21.9% +14.4%
  • ROCKWELL MEDICAL, INC. reported Total Revenue of $57.30 million for fiscal year 2017.
  • ROCKWELL MEDICAL, INC. showed an increase of +7.5% in Total Revenue compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Net Income of -$5.31 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -1007.1% in Net Income compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Diluted EPS of $0.15 per share (loss) for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -400.0% in Diluted EPS compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Total Assets of $57.15 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -3.5% in Total Assets compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Cash and Equivalents of $10.71 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -31.6% in Cash and Equivalents compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Long-Term Debt of $8.83 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed an increase of +4.2% in Long-Term Debt compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Stockholders Equity of $36.98 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed an increase of +13.5% in Stockholders Equity compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported R&D Expense of $0.00 for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -100.0% in R&D Expense compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Operating Income of -$4.69 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -871.5% in Operating Income compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Gross Profit of $11.70 million for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed a decrease of -33.1% in Gross Profit compared to the prior fiscal year.
  • ROCKWELL MEDICAL, INC. reported Shares Outstanding of 39.41 million shares for fiscal year 2025.
  • ROCKWELL MEDICAL, INC. showed an increase of +15.7% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment